Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” Ozempic found outside the authorized drug supply chain. The contents of ...

A Howard County man who went blind after being prescribed Ozempic has sued drug manufacturer Novo Nordisk. Todd Engel was prescribed Ozempic to treat diabetes in August 2023; in late December ...

Compounded versions of Novo Nordisk’s Wegovy and Ozempic will need to stop production soon. Lawsuits over these products are ongoing, but a federal court ruling in Texas means that compounding ...

Novo Nordisk (NVO) won a key case Thursday to stop ... compounded semaglutide — the active ingredient in diabetes drug Ozempic and weight-loss drug Wegovy — next month. That was the deadline ...

The FDA may begin enforcement actions against pharmacies compounding unauthorized semaglutide after May 22, 2025. Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous ...

The US Food and Drug Administration seized fake Ozempic injections. This happened on April 9, 2025. Novo Nordisk warned about these fake drugs. Elon Musk mentioned using a similar drug.

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

A federal court in Texas reportedly dismissed a bid by drug compounders to continue producing off-brand versions of Novo Nordisk‘s weight-loss drug Wegovy and diabetes treatment Ozempic while a ...

Novo Nordisk scored a huge legal victory that largely ... drugmaker's blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. A federal judge in Texas late Thursday rejected a ...

Novo Nordisk works with Hims & Hers ... the active ingredient in Wegovy and Novo's diabetes drug Ozempic, last year. Hims CEO Andrew Dudum said the company will continue to offer personalized ...